Navigation Links
Diabetic in Medical Technology

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

-Clinical Data Presented at American Pain Society Annual Meeting- BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product cand...

ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting...

ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)

LEUVEN, Belgium, March 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, today announces that it has completed patient enrolment for a Phase II trial of microplasmin intr...

Mayo Clinic Discovery May Help Diabetic Gastric Problem

ROCHESTER, Minn., Sept. 25 /PRNewswire-USNewswire/ -- Mayo Clinic researchers have found what may provide a solution to one of the more troubling complications of diabetes -- delayed gastric emptying or gastroparesis. The researchers showed in animal models that a red blood cell derivative incr...

SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI

At One Year, Angioplasty and Stenting Matches Bypass Surgery for Safety and Effectiveness in Patients with Complex Medical Condition WASHINGTON, Sept. 1 /PRNewswire/ -- Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings a...

Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers

FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen ...

Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema

Clinical Program Leverages Quark's RNAi Technology FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initi...

'Snapshots' of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report

FA imaging, invented at U-M, measures metabolic stress in retina ANN ARBOR, Mich., July 14 /PRNewswire-USNewswire/ -- A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complic...

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of ...

Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

Company to Continue Focus on Pipeline and Haptoglobin Diagnostic Assay MONTVALE, N.J., June 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI ) today announced data from three Phase 2 trials (Trials 201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a estab...

Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs

Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the...

New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

Results presented at the 27th Annual Meeting of the American Pain Society (APS) SMYRNA, Ga., May 8 /PRNewswire/ -- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, acco...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

ASHBURN, Va., April 30 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatmen...

Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema

EVRY, France, April 24 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company today announced that it has successfully injected the first patient in a Phase I clinical trial using CORTIJECT(R), an ophthalmic injectable emulsion based on EYEJECT(R) technology platform co...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers

ASHBURN, Va., April 17 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the second of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatm...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

UCB announces clinical data presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controll...

TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials

NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomized clinical trials. The analysis compared the safety and efficacy of the TAXUS(R) Expr...

TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coro...

Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.

SAN DIEGO, March 17 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM ) and its subsidiary, Tissue Repair Company (TRC) today reported that the Phase 2b MATRIX clinical study has been the focus of media attention in multiple regions across the U.S., including television news features ...

MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection

Combined data from two Phase 3 trials show clinical success rates statistically equivalent to oral antibiotic therapy WELLESLEY HILLS, Mass., March 13 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) announced today the presentation of a poster entitled "T...

Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial

SANTA ROSA, Calif., March 12 /PRNewswire/ -- Northern California Foot and Ankle Center Santa Rosa today announced it is recruiting patients with lower extremity diabetic foot ulcers to participate in the MATRIX clinical research trial. The MATRIX trial will study the effects of Excellarate(TM)...

Immunosyn Releases Wound Healing Photographs From the First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019

LA JOLLA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) received permission from Argyll Biotechnologies, LLC to release before and after wound healing photographs resulting from subcutaneous injections of the biopharmaceutical SF-1019 from the first...

Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial

PHOENIX, Feb. 25 /PRNewswire/ -- Associated Foot & Ankle Specialists today announced it is recruiting patients with foot ulcers due to diabetes to participate in the MATRIX clinical trial. The trial will study the effects of a new product, Excellarate, for the potential treatment of patients w...

Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial

TUCSON, Ariz., Feb. 4 /PRNewswire/ -- Aung FootHealth Clinics & Advanced Wound Care Center today announced it is recruiting patients with lower extremity diabetic foot ulcers to participate in the MATRIX clinical trial. The MATRIX trial will study the effects of Excellarate(TM) (GAM501) (Ad5PD...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers

ASHBURN, Va., Dec. 18 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the t...

Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy

Milestone Triggers Payment to Sangamo from JDRF RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center P...

Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema

NEW ORLEANS, La., Nov. 10 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, announced today initial clinical results of an ongoing study for non-thermal Retina Regeneration Therapy (Ellex 2RT(TM))....

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

DOYLESTOWN, Penn., Oct. 25 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY ) today reported net sales of $11.8 million, for the third quarter ended September 30, 2007, compared to $11.5 million reported for the same period in 2006. For the nine-months ended September 30, 2007,...

Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy

- Data to be presented November 2 at the American Society of Nephrology Meeting - SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced that a recently completed phase 2 trial of XL784 did not meet its primary end...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

RARITAN, N.J., Oct. 8 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. today announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including ...

Enrollment Complete in Pivotal Phase 3 Trial of Medidur(TM) FA for Diabetic Macular Edema

ATLANTA, Oct. 8 /PRNewswire/ -- Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (Nasdaq: PSDV; ASX: PSD; Xetra: PSI), announced today that enrollment is complete for the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur(...

MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera

Broadens late-stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis WELLESLEY HILLS, Mass., Oct. 3 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced that it has exercised the option it ...

MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity UNION CITY, Calif., Oct. 1 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced po...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

While no significant differences were found, results showed CYPHER(R) Stent had lower mortality and heart attack rates VIENNA, Austria, Sept. 4 /PRNewswire/ -- A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER(R) Sirolimus...

Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - Avanir Pharmaceuticals (NASDAQ:AVNR) today announced positive top-line results from the company's Phase III clinical trial evaluating the investigational drug Zenvia(TM) (dextromethorphan hydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonis...

Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain

New Analysis Examines Impact of Pain on Sleep Interference INDIANAPOLIS, May 03, 2007 /PRNewswire-FirstCall/ -- Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxet...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-year follow-up subset analysis presented today as a late-breaking clinical trial at EuroPCR 2007 showed that the CYPHER(R) Sirolimus-eluting Coronary Stent had results comparable to coronary artery bypass grafting (CABG or bypass surge...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced positive results for its novel ghrelin agonist, T...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...n episcleral drug reservoir, holds the potential to fundamentally change how we deliver medications to the eye for diseases like macular degeneration, diabetic retinopathy, uveitis, endophthalmitis and retinoblastoma. Working much like an organ-specific transdermal skin patch, the tiny cup isolates the medica...
Other Tags
(Date:8/20/2014)... 2014) Women who are poor experience higher cortisol ... elevated levels of the stress hormone, putting them ... according to a new research from the University of ... the American Journal of Human Biology , is ... it directly to the socioeconomic status of their mothers ...
(Date:8/20/2014)... absorbs light and its energy is finally utilized ... Photovoltaic devices, mostly build from silicon based semiconductors, ... approach for the development of cheaper and renewable ... isolated membrane protein complexes of photosynthesis. Prof. Dr. ... from thermophilic cyanobacteria that live in a hot ...
(Date:8/19/2014)... improve students, chances of completing introductory biology courses ... (UH) implemented a comprehensive student success program, employing ... , Through a grant from the Texas ... Biology and Biochemistry embarked on a pilot program ... non-majors and "Introductory Biology" for science majors. These ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2A semi-artificial leaf faster than 'natural' photosynthesis 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... The non-small cell lung cancer (NSCLC) market value ... the top 8 developed nations, from just over USD ... billion by 2020-end, posting a CAGR of 6.6% during ... driven by innovative therapies entering the squamous cell carcinoma ... the non-squamous segment. Thus, patients with SCC are expected ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the ... company in recent years, developing or acquiring 2 million ... including more than $100 million last year alone. , ... new geographic regions and a wider array of product ... announce an enhanced brand identity that includes a new ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... The award-winning plastic surgery group, The Aesthetic Center ... Houston to a third office, located in Katy, Texas ... ACPS plastic surgeon Dr. Rolando Morales said the expansion ... risen to become one of the largest, most respected ... its establishment in 1996 by plastic surgeons Dr. Christopher ...
Breaking Medicine News(10 mins):Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2
Other Contents